In den Schlagzeilen

Finden Sie interessante News aus den Medien

A pooled analysis of 9 prospective studies involving more than 750,000 adults finds that recommended amounts of leisure-time physical activity were linked to a lower risk for 7 cancers, with several cancer types having a dose/response relationship. Updated guidelines for activity now state that...
Single-agent belantamab mafodotin shows anti-myeloma activity with a manageable safety profile in patients with relapsed or refractory multiple myeloma, according to a study published in The Lancet Oncology. Belantamab mafodotin, an immunoconjugate targeting B-cell maturation antigen, showed...
The US Food and Drug Administration (FDA) has granted supplemental approval to acalabrutinib (Calquence) for the treatment of adults with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). This new approved indication for acalabrutinib provides a new treatment option for...
Young male cancer survivors may significantly benefit from testosterone replacement therapy, especially after testicular cancer, according to a study published in PLOS Medicine. “Cancer and its treatment can be life altering, leaving patients feeling unwell and low in mood,” said Richard Ross, MD...
The US Food and Drug Administration (FDA) has granted accelerated approval to oral zanubrutinib (Brukinsa) for the treatment of adult patients with mantle cell lymphoma who have received at least 1 prior therapy. “Clinical trials showed that 84% of patients saw tumour shrinkage with this therapy...

Kürzlich veröffentlicht

Finden Sie Abstracts aktueller Publikationen

Micol Ravà, Aleco D'Andrea, Paola Nicoli, Ilaria Gritti, Giulio Donati, Mirko Doni, Marco Giorgio, Daniela Olivero, Bruno Amati
Akhil Rajendra, Anup J Devasia, Nirmal Raj Francis, Vijay Prakash Turaka
Caitlin Butler, William Paul Skelton, Arpan Patel, Dhruv Mahtta, Yi Zhuang, Kartik Cherabuddi, Kairav Shah, Merry Markham